Literature DB >> 7799709

End of the New Zealand asthma mortality epidemic.

N Pearce1, R Beasley, J Crane, C Burgess, R Jackson.   

Abstract

In 1989, a case-control study reported that inhaled fenoterol was associated with the epidemic of asthma deaths that had affected New Zealand since 1976. The New Zealand Department of Health issued warnings about the safety of fenoterol and restricted its availability. The associated time trends are consistent with the hypothesis that fenoterol was the main factor in the New Zealand asthma mortality epidemic. The epidemic commenced when fenoterol was introduced in 1976, and the New Zealand death rate remained the highest in the world for more than a decade. After publication of the case-control study, the death rate fell by half and has now remained low for a further 3 years (1990-92). Time-trend data do not suggest a class effect of inhaled beta-agonists in the epidemic: there was no association between beta-agonist sales and the start of the epidemic, and total sales of inhaled beta-agonists actually increased slightly during 1989-90 when the epidemic came to an end. Time-trend data are also inconsistent with the hypothesis that the epidemic may have occurred because of underprescribing of inhaled corticosteroids. Similarly, time-trend data is incosistent with hypotheses postulating a major role of social factors such as unemployment. Data on time trends should be assessed with caution, because time trends in asthma deaths can be affected by many factors. Nevertheless, the New Zealand time trends are consistent with fenoterol being the main cause of the New Zealand asthma mortality epidemic and are inconsistent with a significant role for other suggested causes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7799709     DOI: 10.1016/s0140-6736(95)91159-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.

Authors:  Rui Lin; Simone Degan; Barbara S Theriot; Bernard M Fischer; Ryan T Strachan; Jiurong Liang; Richard A Pierce; Mary E Sunday; Paul W Noble; Monica Kraft; Arnold R Brody; Julia K L Walker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  History of guidelines for the diagnosis and management of asthma: from opinion to control.

Authors:  Claus Kroegel; Hubert Wirtz
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

4.  Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991-2010.

Authors:  Shih-Feng Chiu; Christina M L Kelton; Jeff Jianfei Guo; Patricia R Wigle; Alex C Lin; Sheryl L Szeinbach
Journal:  Am Health Drug Benefits       Date:  2011-05

5.  β-Agonist-mediated relaxation of airway smooth muscle is protein kinase A-dependent.

Authors:  Sarah J Morgan; Deepak A Deshpande; Brian C Tiegs; Anna M Misior; Huandong Yan; Alena V Hershfeld; Thomas C Rich; Reynold A Panettieri; Steven S An; Raymond B Penn
Journal:  J Biol Chem       Date:  2014-06-27       Impact factor: 5.157

6.  How Should We Respond to Non-Dominant Healing Practices, the Example of Homeopathy.

Authors:  Ben Gray
Journal:  J Bioeth Inq       Date:  2016-12-14       Impact factor: 1.352

Review 7.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

Review 8.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

9.  Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.

Authors:  Erik P Riesenfeld; Michael J Sullivan; John A Thompson-Figueroa; Hans C Haverkamp; Lennart K Lundblad; Jason H T Bates; Charles G Irvin
Journal:  Respir Res       Date:  2010-02-24

10.  GPCRs and arrestins in airways: implications for asthma.

Authors:  Raymond B Penn; Richard A Bond; Julia K L Walker
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.